Lesaffre completes Gnosis acquisition
Three years after becoming a majority shareholder in Gnosis, Lesaffre has fully acquired the Italian biotechnology company.
Photo © iStockphoto.com/skynesher
Three years after becoming a majority shareholder in Gnosis (Desio, Italy), Lesaffre (Marcq-en-Baroeul, France) has fully acquired the Italian biotechnology company. Both firms specialize in yeast and fermentation for use in nutraceutical and cosmetic applications.
“For the past three years, we have developed cooperation between Lesaffre and Gnosis teams to become today a unique provider of products and services that are increasingly innovative and closely address our customers’ needs in the nutrition and health sectors,” said Antoine Baule, CEO of Lesaffre, in a press release.
Lesaffre is combining Gnosis with its Lesaffre Human Care business unit to offer a unified range of products and services. Lesaffre Human Care develops and supplies a number of ingredients, including nutritional and fortified yeasts, yeast fractions, probiotic yeasts and bacteria, and pure molecules for wide range of applications such as digestive health, immune health, joint health, liver health, women’s health, and personal care.
“Developing Gnosis has been an exciting challenge,” said Renzo Berna, former CEO of Gnosis, in a press release. “After 25 years, Gnosis has become a reference on the market able to design and manufacture fermentation purified metabolites as healthcare active ingredients for the nutraceutical and pharmaceutical markets. I am convinced that Lesaffre, a family group known and recognized internationally for its professionalism and the quality of its products and services, will take this company even further forward.”
Kratom sees impressive sales growth despite its regulatory status and stigma
March 12th 2025Despite its controversy, kratom is a top-selling ingredient that consumers see value in. That said, brands need to work hard to demonstrate safety and quality of kratom products in the absence of legal regulatory status. Will kratom be able to overcome its stigma for even more growth and consumer acceptance?
DOJ asks Utah court to dismiss FTC lawsuit against Xlear Inc.
March 11th 2025On March 10, the DOJ and the defendant filed a stipulation to dismiss with prejudice the lawsuit in which each party agrees “to be responsible for its own costs and fees and agrees that no party shall be responsible to any other party for any fines, costs, fees, or penalties arising from this case.”
HHS announces efforts to eliminate independent conclusion of GRAS
Published: March 11th 2025 | Updated: March 11th 2025U.S. Department of Health and Human Services (HHS) Secretary, Robert F. Kennedy Jr., is directing the acting U.S. Food and Drug Administration’s (FDA) acting commissioner to explore rulemaking that would eliminate the independent conclusion of GRAS provision.
